Google
IVVD 株価分析 — INVIVYD INC. (Healthcare >> Biotechnology)
IVVD に関するよくある質問
IVVDのROE（自己資本利益率）は？
INVIVYD INC.のROEは-38.22%です。
IVVDの配当利回りは？
INVIVYD INC.の配当利回りは0.00%です。
IVVDの品質スコア（Quality Score）は？
当社のAIはIVVDの総合財務品質を100点中31点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
IVVDは今が買い時ですか？
当社AIのタイミングスコアは100点中26点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
IVVDはどのセクターに属しますか？
INVIVYD INC.はHealthcare >> Biotechnologyセクターに分類されます（NASDAQ市場）
IVVD AI Analysis Summary
Our AI summary for IVVD: INVIVYD INC. (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -38.22%, a dividend yield of 0.00%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 26/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 0.54
Price
-0.05
(-8.01%)
Day Change
|
|
|---|
IVVD, ファンダメンタルスコアはnot good ( ファンダメンタル = 31) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
平均ROEが低い
ROEが昨年度比で低い
ROAがROEに比べて低い
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 94 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 0.54 |
| PBV / Sector |
0.84 / 5.20
GREAT
|
| Earning Per Share | -0.24 |
| PE / Sector |
N/A / 19.97
|
| PEG or PE/Growth / Sector |
N/A / 1.22
|
| Average 1M Daily Value |
2.46 M
GREAT
|
| Average 1W Daily Value |
1.82 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
52% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-01 08:00:02 |
| Symbol | IVVD |
| Name | INVIVYD INC. |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 294.61 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 171.34 / 9,903.94 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 209 Church Street, New Haven, CT, United States, 06510
Phone: 781 819 0080
Website: https://www.invivyd.com
Employees: 122
Sector: Healthcare >> Biotechnology
Description: Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand. It also develops VYD2311, a monoclonal antibody, which is in Phase III clinical trial for the prevention and treatment of SARS-CoV-2 virus; and VBY329, a monoclonal antibody, which is in pre-clinical trial stage for the prevention and treatment of respiratory syncytial virus and measles in neonates, infants, and children. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in New Haven, Connecticut.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
